Hydrocortison Tiofarma

Hydrocortison Tiofarma is a medication that contains the corticosteroid hydrocortisone as its active ingredient. The product’s strength and dosage form are not specified in the available information, and it is intended for oral administration. Marketed in the European Union, Hydrocortison Tiofarma belongs to the glucocorticoid therapeutic class and is used under medical supervision for conditions requiring anti‑inflammatory or hormone replacement therapy as part of a comprehensive treatment plan.

Hydrocortison Tiofarma is prescribed for several medical conditions that involve cortisol deficiency or excessive inflammation.

- Replacement therapy for primary or secondary adrenal insufficiency. - Management of acute or chronic inflammatory disorders such as dermatitis, arthritis, or ulcerative colitis. - Treatment of severe allergic reactions, including anaphylaxis adjunct therapy. - Control of autoimmune conditions where immune suppression is required.

Like other systemic corticosteroids, Hydrocortison Tiofarma may cause a range of adverse reactions, varying in frequency and severity.

Common: - Mild gastrointestinal discomfort or nausea. - Transient increase in blood glucose levels. - Fluid retention leading to mild swelling. - Mood changes such as irritability or insomnia.

Serious: - Signs of infection due to immune suppression. - Severe hypertension or electrolyte imbalance. - Adrenal crisis on abrupt discontinuation.

Healthcare providers should evaluate several factors before initiating Hydrocortison Tiofarma therapy.

- Assess for active infections or uncontrolled diabetes before use. - Monitor blood pressure, blood glucose, and electrolyte levels regularly. - Use the lowest effective dose for the shortest duration possible. - Consider alternative therapies in patients with known hypersensitivity to corticosteroids. - Counsel patients on the risk of adrenal suppression with prolonged treatment. - Avoid use during pregnancy or lactation unless benefits outweigh risks (consult physician).

Hydrocortison Tiofarma can interact with other medicines, affecting its efficacy or safety profile.

Avoid: - Concurrent use with potent CYP3A4 inducers (e.g., rifampin, phenytoin) may reduce hydrocortisone levels. - Combining with systemic immunosuppressants (e.g., cyclosporine) can increase infection risk. - Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs) may raise the chance of gastrointestinal bleeding.

Use with caution: - Concurrent use with anticoagulants (e.g., warfarin) may enhance anticoagulant effect. - Combining with antidiabetic agents may require dose adjustments due to altered glucose control. - Use with vaccines, especially live attenuated, should be carefully considered.